PharmaNewsIntelligence ranked 45th on FeedSpot's list of top 60 pharma news websites! Check out the entire list here: https://lnkd.in/gVNiTcyK.
PharmaNewsIntelligence
Online Audio and Video Media
Danvers, Massachusetts 411 followers
Leveraging Drug Innovations to Deliver Better Care
About us
The editors at PharmaNewsIntelligence share insights with providers and payers interested in the impact of pharmaceuticals on healthcare spending, quality of care, and breakthrough therapies.
- Website
-
https://pharmanewsintel.com/
External link for PharmaNewsIntelligence
- Industry
- Online Audio and Video Media
- Company size
- 11-50 employees
- Headquarters
- Danvers, Massachusetts
Updates
-
PharmaNewsIntelligence reposted this
The World Health Organization (WHO) and UNICEF issued a joint news release revealing that global childhood immunization rates stalled in 2023, leaving many children and adolescents unprotected against preventable diseases. “Overall, this data indicates a need for more public health efforts that promote pediatric vaccinations to prevent disease outbreaks and protect global populations.” Xtelligent Healthcare Media’s Veronica Salib has the story for PharmaNewsIntelligence: https://bit.ly/4d4ECmi | #Immunizations #PedsImmunizations #PtSafety #PublicHealth
Global pediatric immunization rates stall, threatening public health
pharmanewsintel.com
-
Join us for an insightful webcast on BrightTALK, "Characterizing the Reimbursement Landscape for Cell and Gene Therapies," presented by Monet Stanford, PharmD, Director of Access & Reimbursement Policy, Alliance for Regenerative Medicine. 📅 Date: September 18, 2024 🕒 Time: 11:00 AM EDT 💻 Where: Online (BrightTALK Platform) About this talk: The rapid advancements in cell and gene therapies have transformed the treatment landscape for various conditions, including cancer, genetic disorders, and autoimmune diseases. However, the reimbursement environment for these groundbreaking therapies presents unique challenges and opportunities. In this session, Monét Stanford, PharmD, will explore the current realities of the payer environment, focusing on Medicare and Medicaid and the emerging models of value-based pricing and outcomes-based agreements. This is a fantastic opportunity to learn from an industry expert, network with like-minded professionals, and explore cutting-edge ideas shaping the future of regenerative medicine. Plus, it's FREE to register! 👉 Register here: https://lnkd.in/g2uZJ_CV Don't miss this chance to gain valuable insights and drive your career forward. See you there! #Innovation #Advancements #GeneTherapy #CellTherapy #FreeEvent #BrightTALK
Characterizing the Reimbursement Landscape for Cell and Gene Therapies
brighttalk.com
-
Teva launches authorized generic of Victoza (liraglutide) in the United States, potentially reducing costs, improving access, and enhancing diabetes care outcomes. Written by Alivia Kaylor, MSc #glp1 #genericdrugs #diabetes https://lnkd.in/eQZJMJzz
Teva launches authorized generic of Victoza in the US
pharmanewsintel.com
-
The endocannabinoid system, a complex cell-signaling network, is vital in maintaining physiological balance by regulating key processes such as mood, pain, and immune response. Written by Alivia Kaylor, MSc #cannabis #cns #ecs https://lnkd.in/eDHByv_Q
Understanding the endocannabinoid system’s role in maintaining physiological balance
pharmanewsintel.com
-
A report from the Congressional Budget Office estimates that doubling hepatitis C treatment among Medicaid enrollees could save $7 billion. Written by Veronica Salib #budget #hepatitis #medicaid https://lnkd.in/e_BW9wxb
Expanding access to hepatitis C treatment would reduce healthcare cost
pharmanewsintel.com
-
The new vaccine is thought to protect against approximately 85% of invasive pneumococcal disease in adults 65 years of age and older. Written by Veronica Salib #pcv #infectiousdisease #vaccines https://lnkd.in/eeySGH3Y
FDA approves Merck’s newest pneumococcal vaccine
pharmanewsintel.com
-
The tool is marketed as a suite of central laboratory solutions for investigator sites, which should accelerate the speed of trials. Written by Veronica Salib #clinicaltrials #diversity #research https://lnkd.in/ecVaBCHV
Labcorp Global Trial Connect offers tools for clinical trials
pharmanewsintel.com
-
The USP's 2023 report highlights economic factors driving drug shortages, emphasizing the need for policy reforms, pricing adjustments, and supply chain diversification. Written by Alivia Kaylor, MSc #drugshortages #policy #supplychain https://lnkd.in/e4j8fwbi
2023 USP Report highlights economic factors driving drug shortages
pharmanewsintel.com
-
Although up to 82% of plans cover GLP-1 medications for diabetes, 1% or less cover GLP-1 drugs for obesity, such as Saxenda, Wegovy, and Zepbound. Written by Veronica Salib #glp1 #obesity #diabetes https://lnkd.in/ec7Jhbnr
Only 1% of ACA Marketplace plans cover GLP-1 drugs for obesity
pharmanewsintel.com